A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option
Peking University · Peking University First Hospital · +2 more institutions
Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with…
Citation impact
- FWCI
- 12.20
- Percentile
- 100%
- References
- 33
Authors
5- TYTiantian Yao
Peking University, Peking University First Hospital
- JQJiandan Qian
Peking University, Peking University First Hospital
- WZWen‐Yan Zhu
Peking University, Peking University First Hospital
- YWYan WangCorresponding
Peking University, Peking University First Hospital
- GWGui‐Qiang WangCorresponding
Peking University, Peking University First Hospital, Peking University International Hospital, Zhejiang University
Topics & keywords
- Coronavirus
- Virology
- Coronavirus disease 2019 (COVID-19)
- Lopinavir
- 2019-20 coronavirus outbreak
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Medicine
- Severe acute respiratory syndrome coronavirus
- Good health and well-being